Get started
Author

Jianrui Hou

Observed institution: Boehringer Ingelheim (Japan)
OpenAlex ID: A5000265286
Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors
2023 · Noboru Yamamoto, Takafumi Koyama, et al. · Cancer Chemotherapy and Pharmacology · 11
Phase I study of BI 754091 plus BI 754111 in Asian patients with gastric/gastroesophageal junction or esophageal cancer.
2021 · Kensei Yamaguchi, Yoon-Koo Kang, et al. · Journal of Clinical Oncology · 7
An open-label, phase Ib dose-expansion study to assess the efficacy of CD137/FAP agonist BI 765179 plus pembrolizumab as a first-line treatment in metastatic or incurable, recurrent programmed cell death ligand-1 (PD-L1)-positive head and neck squamous cell carcinoma (HNSCC).
2025 · Rachna T. Shroff, Dejan Radonjic, et al. · Journal of Clinical Oncology · 1
PDF
Abstract CT110: An open-label, phase Ib dose-expansion study to assess the efficacy of CD137/FAP agonist BI 765179 plus pembrolizumab as a first-line treatment in metastatic or incurable, recurrent programmed cell death ligand-1 (PD-L1)-positive, head and neck squamous cell carcinoma (HNSCC)
2025 · Rachna T. Shroff, Dejan Radonjic, et al. · Cancer Research · 1
A phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors.
2024 · Toshihiko Doi, Noboru Yamamoto, et al. · Journal of Clinical Oncology · 1
PDF
Abstract CT080: Open-label, Phase Ib dose-expansion study assessing the efficacy of the CD137/FAP agonist BI 765179 plus pembrolizumab as first-line therapy in metastatic or incurable, recurrent PD-L1-positive head and neck squamous cell carcinoma
2026 · Rachna T. Shroff, Dejan Radonjic, et al. · Cancer Research
Abstract LB-A002: Open-label, Phase Ib dose-expansion study assessing the efficacy of the CD137/FAP agonist BI 765179 plus pembrolizumab as first-line therapy in metastatic or incurable, recurrent PD-L1-positive head and neck squamous cell carcinoma
2026 · Rachna T. Shroff, Dejan Radonjic, et al. · Cancer Immunology Research
MO20-2 Phase I study of BI 754091 plus BI 754111 in Asian patients with gastric/gastroesophageal junction or esophageal cancer
2021 · Do-Youn Oh, Yoon-Koo Kang, et al. · Annals of Oncology
Works count: 8
Citation count: 21
H-index: 2
I10-index: 1
Year
Topic
Type